1. Ethics & Compliance
  2. Physician & Other Payments

Physician payments & other transfers
of value

We’re guided by openness and transparency in our relationships with health care providers (HCPs), health care organizations (HCOs) and patient organizations.

We believe interactions with health care professionals bring value to patient care

AbbVie is committed to collaborating with health care professionals (HCPs), health care organizations (HCOs) and patient organizations to improve patient health across the globe. Our interactions with HCPs, HCOs and patient organizations are guided by openness and transparency to ensure public trust and confidence. AbbVie supports disclosure of these relationships wherever possible to demonstrate the integrity of our relationships with HCPs, HCOs and
patient organizations.

HCP/HCO disclosures inside the US

Open payments—Physician Payments Sunshine Act

The US Sunshine Act, also known as the Open Payments—Physician Payments Sunshine Act, was enacted as federal law in 2010 as a component of the Affordable Care Act. The Act requires health care manufacturers, including AbbVie, to track financial transactions with certain health care providers and health care organizations (HCOs) and to disclose those transactions on an annual basis. We support the Act and its goal of providing the public greater visibility into interactions between the health care industry and HCPs to ensure public trust and confidence. To learn more, view our FAQs.

Report information

The report is based on transactional data that has been aggregated at a particular point in time; some payments and transfers of value that take place during the reporting period may be included in the next quarter’s report. Posted data may not correlate to state transparency reports due to differences in the scope and requirements between the various transparency laws. Changes or additions that are identified after the report is posted will be accounted for in the next quarter’s report. Due to the requirements for reporting related entities/payees, some payments shown on the report are included more than once. The types of payments and transfers of value included in the report are as follows:

  • Business meals, which include reimbursed amounts for meals incurred in the course of providing contracted-for services such as consulting and research; and meals provided in connection with an educational or business discussion
  • Business travel, which includes reimbursed amounts and the value of directly provided transportation (e.g., airfare, taxi service) incurred in the course of providing contracted-for services such as consulting and research
  • Educational materials and items, which include reference materials such as journal articles, textbooks and anatomical models
  • Professional services, which include payments for contracted-for services such as speaking at an educational seminar or serving on a data safety monitoring board
  • Research-related payments, which include payments for research and clinical trial activities, royalties and license fees
  • Job interview-related payments, such as flights, meals, hotel, area tours, etc. Your collected information will only be released on the public website if you are selected to interview and have expenses paid for or reimbursed to you by AbbVie. Additionally, Massachusetts and Vermont have expanded rulings that require interview-related expenses to be reported for “Health Care Providers & Practitioners.” Expenses incurred during the interview process may be reported under the Federal Sunshine Act (and other state laws)

For physician payment reports, AbbVie follows the annual de minimis threshold reporting guidance as provided by CMS for Open Payments reporting.

HCP/HCO disclosures outside of the US

Information exchanged with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs) and patient organizations leads to newer and better therapies and, most importantly, enhanced care for patients. We believe interactions with healthcare professionals and healthcare organizations are essential to advance patient care, gain insights into unmet medical needs and progress the development of new medicines. Our interactions with HCPs and HCOs are based on trust, transparency and integrity, with a goal of providing the public with greater visibility into these interactions to ensure public trust and confidence. AbbVie engages in a range of activities from clinical research to sponsorships to educational activities to exchange information on how new medicines fit into the patient pathway. By bringing greater transparency to these relationships, AbbVie demonstrates its ongoing commitment to strengthening the basis for future collaboration.

Expand All

Australia
Disclosure data

Japan
Disclosure data

Republic of Korea - Data available upon request by the Ministry of Health and Welfare, an HCP or HCO

Transparency throughout our industry is a cornerstone of the pact of trust we have with patients and society. As such, AbbVie is proud to disclose our data on transfers of value to HCPs and HCOs in Europe in accordance with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code, national laws and regulations and country-specific industry codes. In addition, AbbVie has annually published data regarding the financial support we provide to European Patient Organizations since 2010.

Austria
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Belgium
2016 – Disclosure Data
2017 – Disclosure Data
2018 – Disclosure Data

Bosnia & Herzegovina - More information coming soon

Bulgaria
2015 – Disclosure Report, Additional Document
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Croatia
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Cyprus
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Czech Republic
2016 – Disclosure Data
2017 – Disclosure Data
2018 – Disclosure Data

Estonia
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Finland
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

France
2016 - Disclosure Data
2017 - Disclosure Data
2018 - Disclosure Data

Germany
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Greece
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Hungary
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Iceland  
2016 – Disclosure Data
2017 – Disclosure Data
2018 – Disclosure Data

Ireland
2016 – Disclosure Data
2017 – Disclosure Data
2018 – Disclosure Data

Italy
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Latvia
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Lithuania
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Luxembourg
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Malta
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Netherlands
2016 – Disclosure Data
2017 – Disclosure Data
2018 – Disclosure Data

Norway
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Poland
2016 – Disclosure Report,  Additional Document
2017 – Disclosure Report,  Additional Document
2018 – Disclosure Report,  Additional Document

Portugal
Disclosure Data*

*Please use Google Chrome to view this link.

Romania
2016 – Disclosure Data
2017 – Disclosure Data
2018 – Disclosure Data

Russia
2016 – Disclosure Data
2017 – Disclosure Data
2018 – Disclosure Data

Serbia
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Slovakia
2016 – MoH Disclosure Data
2016 – AIFP Disclosure Report, AIFP Additional Document
2017 – MoH Disclosure Data
2017 – AIFP Disclosure Report, AIFP Additional Document
2018 – MoH Disclosure Data
2018 – AIFP Disclosure Report, AIFP Additional Document
2019 – MoH Disclosure Data

Slovenia
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Spain
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Sweden
2016 – Disclosure Data
2017 – Disclosure Data
2018 – Disclosure Data

Switzerland
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

Turkey – Data submitted per Ministry of Health requirement

Ukraine
2016 – Disclosure Report, Additional Document
2017 – Disclosure Report, Additional Document
2018 – Disclosure Report, Additional Document

United Kingdom
2016 – Disclosure Data
2017 – Disclosure Data
2018 – Disclosure Data

EFPIA Disclosure Code—2016 Self-Certification Scheme

EFPIA Disclosure Code—2017 Self-Certification Scheme

EFPIA Disclosure Code—2018 Self-Certification Scheme

Brazil (Minas Gerais) -  Disclosure Data

Colombia - More information coming soon

Mexico - More information coming soon

Saudi Arabia - Data submitted per the Saudi Food and Drug Authority requirement

European patient organization relationships

AbbVie is committed to making a remarkable impact on patients’ lives and their caregivers.  We combine advanced science with a deep knowledge of the patient experience and healthcare systems to help people live better, more productive lives. We pursue learning about patient experiences to understand the issues, concerns and priorities of people affected by disease.

Patient organizations are a source of valuable information and support for patients and their caregivers. We foster patient organization relationships based on mutual trust, respect and goals that reflect AbbVie’s transparent and ethical behavioral standards. Through these relationships, AbbVie contributes to informing patients and caregivers about disease states, treatment options and how to improve quality of life. These partnerships facilitate dialogue between interested parties and help create new, cost-effective health care delivery models.

Annually, AbbVie publishes a list of its financial support of European Patient Organizations. Our publication of the following report demonstrates our commitment to transparent disclosure of our financial relationships with patient organizations.

AbbVie’s 2018 European Patient Organization Report

*Please note that the report includes support values for Belgium, France, Netherlands, Romania, Portugal and Turkey, which are also disclosed as part of their local Transparency legislation.

Serbia – Sponsored Professional Conferences

AbbVie has a long-standing commitment to supporting programs aimed at increasing the understanding of scientific, clinical and health care issues that improve patient care. In the interest of transparency, we are disclosing the following list of professional conferences sponsored by AbbVie.

Sponsored Professional Conferences 2013
Sponsored Professional Conferences 2014
Sponsored Professional Conferences 2015
Sponsored Professional Conferences 2016
Sponsored Professional Conferences 2017
Sponsored Professional Conferences 2018
Sponsored Professional Conferences 2019

Ethics & compliance

Ethics & Compliance Program

Ethics & compliance

AbbVie Code of Business Conduct